NEW TECH FOODS

UK biotech company CellRev has ceased trading after failing to secure Series A investment, CEO Chris Green confirmed in a LinkedIn post.

Founded by Martina Miotto, CellRev set out to transform bioprocessing with an industry-first continuous adherent cell manufacturing platform. The company demonstrated 60 days of continuous culture, secured its first strategic partnerships and filed three patent families.

However, the company’s initial target market was heavily impacted by wider industry shifts from late 2022 onwards. In response, CellRev pivoted to focus on reagents and life science applications, eventually concentrating on vaccines as a beachhead.

Between 2024 and 2025, the company developed a data set showing a three-fold viral titre increase, with third-party validation confirming earlier viral peaks in a measles process. It secured its first commercial partnerships, with pilots already underway and expanded into the Cell & Gene Therapy market through additional collaborations

During the same period, CellRev established distribution partnerships, attracted continuing customer enquiries and gained recognition as one of just 20 companies selected for the BioTools Innovator Program. The team also brought on experienced industry advisors to strengthen its commercial and scientific strategy.

Despite these achievements, CellRev was unable to meet commercial milestones quickly enough to attract Series A investors.

“The bar is higher than anyone (in 2021) could have foreseen, and we were operating in Life Sciences (if you know you know),” said Green. “We are still adamant that what CellRev set out to do is transformative and very much needed; however, we ran out of time.”

Green thanked past and present employees, partners and supporters, noting that CellRev’s journey delivered valuable learnings and forged strong industry connections.

Top image: © CellRev